Business Context and Reporting Period
This Form 8-K is a current report filed by SELLAS Life Sciences Group, Inc. on March 11, 2026. The filing addresses "Other Events" (Item 8.01) related to capital raises through warrant exercises occurring after the end of the 2025 fiscal year.
Key Financial Metrics
- Warrant Proceeds (Post-Dec 31, 2025): Approximately $42.6 million in total proceeds received from the exercise of common stock warrants.
- Recent Proceeds (Since Jan 8, 2026): Approximately $16.1 million.
- Prior Proceeds (As of Jan 8, 2026): Approximately $26.5 million.
- Shares Outstanding (As of Mar 11, 2026): 179,536,724 shares of common stock.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, net income, operating cash flow, or specific liquidity ratios beyond the warrant proceeds noted above.
- Debt and Margins: The filing text does not provide a clear value for debt levels or profit margins.
Material Changes
The primary material change reported is the significant increase in cash proceeds from warrant exercises. Between January 8, 2026, and March 11, 2026, the company secured an additional $16.1 million, bringing the total post-year-end capital raised to $42.6 million. This activity has also resulted in an updated share count of approximately 179.5 million shares outstanding as of the filing date.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the warrant exercises. No unusual items or contingencies are detailed in this specific report.
Investor Verification Checklist
- Verify the exact number of shares issued in the $16.1 million warrant exercise to calculate the weighted average price per share.
- Confirm the updated total share count of 179,536,724 against the company's latest 10-K or 10-Q filings to assess dilution impact.
- Review the company's cash balance in the most recent quarterly report to determine the total liquidity position after adding the $42.6 million in proceeds.
- Check for any remaining unexercised warrants that could lead to further dilution in the near term.